LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the safety, tolerability and efficacy of LUT014 gel topically
administered in breast cancer patients who developed radiation dermatitis. Subjects enrolled
to part 1 will be enrolled to receive the study treatment (open label treatment) for 28 days
and will be followed up for 2 months after the completion of study treatment. Subject in Part
2 will be randomized in 1:1 ratio to receive either the study drug or placebo (double-blind
treatment) for qd topical application for 28 days and will be followed up for 2 months after
the completion of study treatment.